We are live on ! Find out more
PLSE icon

Pulse Biosciences

84 hedge funds and large institutions have $91.7M invested in Pulse Biosciences in 2025 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 23 increasing their positions, 29 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

44% more call options, than puts

Call options by funds: $1.49M | Put options by funds: $1.03M

15% more funds holding

Funds holding: 7384 (+11)

0.44% less ownership

Funds ownership: 9.7%9.26% (-0.44%)

12% less capital invested

Capital invested by funds: $104M → $91.7M (-$12.2M)

21% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 29

Holders
84
Holders Change
+11
Holders Change %
+15.07%
% of All Funds
1.13%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
17
Increased
23
Reduced
29
Closed
6
Calls
$1.49M
Puts
$1.03M
Net Calls
+$457K
Net Calls Change
-$353K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$21.7M -$396K -21,222 -2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$13.6M -$5.65M -303,285 -26%
Bank of America
3
Bank of America
North Carolina
$12.5M -$199K -10,693 -1%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$7.5M +$92.3K +4,952 +1%
State Street
5
State Street
Massachusetts
$6.75M -$1.03M -55,006 -12%
GAM
6
Griffin Asset Management
New York
$3.76M -$74.4K -3,990 -2%
Northern Trust
7
Northern Trust
Illinois
$3.29M -$111K -5,953 -3%
Charles Schwab
8
Charles Schwab
California
$2.41M +$8.07K +433 +0.3%
Millennium Management
9
Millennium Management
New York
$1.39M +$1.61M +86,574 New
Renaissance Technologies
10
Renaissance Technologies
New York
$1.09M +$1.26M +67,800 New
WIM
11
Westside Investment Management
California
$936K +$56.6K +3,034 +6%
N
12
Nuveen
North Carolina
$915K
UBS Group
13
UBS Group
Switzerland
$881K +$507K +27,194 +99%
PC
14
Panoramic Capital
California
$848K +$77.4K +4,152 +9%
PW
15
Pandora Wealth
Illinois
$828K +$959K +51,452 New
Squarepoint
16
Squarepoint
New York
$827K +$958K +51,418 New
Morgan Stanley
17
Morgan Stanley
New York
$811K -$211K -11,310 -18%
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$645K +$139K +7,451 +23%
Goldman Sachs
19
Goldman Sachs
New York
$628K -$209K -11,208 -22%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$617K -$9.02K -484 -1%
UBS AM
21
UBS AM
Illinois
$588K -$33.1K -1,777 -5%
State of Wisconsin Investment Board
22
State of Wisconsin Investment Board
Wisconsin
$497K -$1.73K -93 -0.3%
RhumbLine Advisers
23
RhumbLine Advisers
Massachusetts
$440K +$30.1K +1,614 +6%
TIAA Trust, National Association
24
TIAA Trust, National Association
North Carolina
$439K
Barclays
25
Barclays
United Kingdom
$431K -$113K -6,067 -18%

PLSE Hedge Fund Activity: Q1 2025 in Review

84 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Pulse Biosciences (PLSE) for Q1 2025, worth a combined $91.7M — down 12% from $104M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new PLSE positions and 6 closed out — a net gain of 11 holders — while 23 added to existing stakes and 29 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $1.61M. The largest seller was Vanguard Group, cutting an estimated $5.65M.

  • 84 institutional investors held Pulse Biosciences (PLSE) as of Q1 2025, up from 73 in Q4 2024.
  • Funds reported $91.7M of Pulse Biosciences stock for Q1 2025, down 12% quarter-over-quarter.
  • 17 funds opened new Pulse Biosciences positions in Q1 2025 and 6 closed out, a net change of +11 holders.
  • The largest Pulse Biosciences buyer in Q1 2025 was Millennium Management, an estimated $1.61M added.
  • The largest Pulse Biosciences seller in Q1 2025 was Vanguard Group, an estimated $5.65M sold.

Based on aggregated 13F filings for Q1 2025.